Corvus Pharmaceuticals, Inc. (CRVS) Stock Analysis

Q: What is the CRVS stock price target?

Take-profit $29.00 (+137.9% upside). Target $29.00 (+133.5%), stop $11.34 (−9.5%), A.R:R 9.2:1.

Q: What are the risks of investing in CRVS?

Market cap $0.97B below $1B minimum; Market cap $0.97B below $1B minimum; Momentum score 3.6/10 — below 4.5 minimum.

Q: Is CRVS overvalued or undervalued?

Corvus Pharmaceuticals, Inc. trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 9.0/10. Overall verdict: Hold.

Q: What do analysts say about CRVS?

13 analysts cover CRVS with a consensus score of 4.2/5. Average price target: $33.

HoldVALUE-TRAP 1/5Moderate ConfidenceUpdated 49 min ago (May 20, 2026, 5:12 PM ET)

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $12.42, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum.

$12.42+137.9% A.UpsideScore 5.1/10#75 of 157 Biotechnology

QualityF-score4 / 9FCF yield-2.33%

Stop $11.34Target $29.00(analyst − 13%)A.R:R 9.2:1

Analyst target$33.33+168.4%6 analysts

$29.00our TP

$12.42price

$33.33mean

$42

Hold if already holding. Not a fresh buy at $12.42, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.97B below $1B minimum. Not in investable universe. Score 5.1/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Corvus Pharmaceuticals, Inc.

Latest news

Corvus Pharma Q1 EPS $(0.15), Inline — benzinga May 7, 2026 neutral
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Gol — benzinga Apr 17, 2026 positive
Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings — benzinga Apr 17, 2026 neutral
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Fr — benzinga Apr 17, 2026 positive
This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday — benzinga Apr 17, 2026 positive

Generated 2026-05-20T22:01:21Z.

Thesis

Rewards

No bull case signals

Risks

Market cap $0.97B below $1B minimum

Key Metrics

P/E (TTM)—

P/E (Fwd)-12.1

Mkt Cap$967M

EV/EBITDA-15.3

Profit Mgn0.0%

ROE-30.5%

Rev Growth—

Beta0.94

DividendNone

Rating analysts13

Quality Signals

Piotroski F4/9

Options Flow

P/C0.21bullish

IV81%elevated

Max Pain$1-91.9% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.515%0.22

Growth5.015%0.75

Momentum3.610%0.36

Sentiment7.510%0.75

Insider Activity5.010%0.50

Peer Rank5.810%0.58

Technical Setup5.85%0.29

Risk Profile3.85%0.19

Catalyst3.05%0.15

Overall (Σ contributions)5.15

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Moat

4.0

Piotroski F

4.4

Current Ratio

5.0

Cash-burning (FCF negative)No competitive moatQuality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

0.9

Earnings History

1.1

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/2M

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Obv

1.0

Ma Position

4.0

Volume

5.0

Rsi

8.2

Uptrend pullback (RSI 33) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

GatesMomentum 3.6<4.5A.R:R 9.2 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

33 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $11.42Resistance $17.89

Price Targets

$11

$29

A.Upside+133.5%

A.R:R9.2:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Market cap $0.97B below $1B minimum

! Momentum score 3.6/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-08-06 (78d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is CRVS stock a buy right now?

Hold if already holding. Not a fresh buy at $12.42, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.97B below $1B minimum. Not in investable universe. Target $29.00 (+133.5%), stop $11.34 (−9.5%), A.R:R 9.2:1. Score 5.1/10, moderate confidence.

What is the CRVS stock price target?

Take-profit target: $29.00 (+137.9% upside). Target $29.00 (+133.5%), stop $11.34 (−9.5%), A.R:R 9.2:1. Stop-loss: $11.34.

What are the risks of investing in CRVS?

Market cap $0.97B below $1B minimum.

Is CRVS overvalued or undervalued?

Corvus Pharmaceuticals, Inc. trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 9.0/10. Verdict: Hold.

What do analysts say about CRVS?

13 analysts cover CRVS with a consensus score of 4.2/5. Average price target: $33.

What does Corvus Pharmaceuticals, Inc. do?Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product...

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.